Literature DB >> 2156997

Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.

H Nagaya1, H Satoh, Y Maki.   

Abstract

We have reported previously that 2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridyl]methyl] sulfinil]- 1H-benzimidazole (AG-1749) inhibits (H+ + K+)-adenosine triphosphatase after being transformed into its cyclic sulfenamide form (AG-2000) or disulfide form (AG-1812) under acidic conditions. In this study, mechanisms related to the inhibition of acid formation by AG-1749 were investigated in isolated canine parietal cells. AG-1749 suppressed the acid formation stimulated by histamine, carbachol or dibutyryl cyclic AMP with IC50 values of approximately 0.09 microM: AG-1749 being twice as potent as omeprazole. The inhibitory effect of AG-1749 was antagonized by dithiothreitol (1 mM). 2-Cyclo-hexen-1-one (3 mM) decreased cytosolic glutathione to less than 10% of control value, and caused a 3-fold increase in the inhibitory effect of AG-1749. Glutathione, however, when added exogenously, did not affect the action of AG-1749. The inhibition was reversed by removing AG-1749 from the medium or by adding dithiothreitol (1 mM). The reversal of inhibition by these two procedures was hardly affected by puromycin (100 microM) or cycloheximide (300 microM) but significantly prevented by 2-cyclo-hexen-1-one (1 mM). Exogenously added AG-2000 (10 microM) or AG-1812 (5 microM), active forms of AG-1749, did not inhibit acid formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156997

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.

Authors:  Z Hussein; G R Granneman; D Mukherjee; E Samara; D L Hogan; M A Koss; J I Isenberg
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer.

Authors:  Shun Kobayashi; Noriko Nakajima; Yoko Ito; Mitsuhiko Moriyama
Journal:  J Gastroenterol       Date:  2010-03-24       Impact factor: 7.527

3.  Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.

Authors:  Masatomo Miura; Hitoshi Tada; Norio Yasui-Furukori; Tsukasa Uno; Kazunobu Sugawara; Tomonori Tateishi; Toshio Suzuki
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

4.  Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.

Authors:  T O Kovacs; D Campbell; M Haber; P Rose; D E Jennings; J Richter
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

5.  Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.

Authors:  Chise Kodaira; Mitsushige Sugimoto; Masafumi Nishino; Mihoko Yamade; Naohito Shirai; Shinya Uchida; Mutsuhiro Ikuma; Shizuo Yamada; Hiroshi Watanabe; Akira Hishida; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2009-02-24       Impact factor: 2.953

6.  Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.

Authors:  Masato Saito; Norio Yasui-Furukori; Tsukasa Uno; Takenori Takahata; Kazunobu Sugawara; Akihiro Munakata; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

7.  Pharmacokinetics of lansoprazole and its main metabolites after single and multiple intravenous doses in healthy Chinese subjects.

Authors:  Dan Zhang; Yanan Zhang; Man Liu; Xiaolin Wang; Man Yang; Jing Han; Huichen Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-12-11       Impact factor: 2.441

8.  Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick.

Authors:  Vicky E Macrae; Megan G Davey; Lynn McTeir; Sonoko Narisawa; Manisha C Yadav; Jose Luis Millan; Colin Farquharson
Journal:  Bone       Date:  2010-01-04       Impact factor: 4.398

9.  Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.

Authors:  M Miura; H Tada; N Yasui-Furukori; T Uno; K Sugawara; T Tateishi; T Suzuki
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

Review 10.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

Authors:  L B Barradell; D Faulds; D McTavish
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.